Patrizia Trenta
Overview
Explore the profile of Patrizia Trenta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
269
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Iacovelli R, Palazzo A, Procopio G, Santoni M, Trenta P, De Benedetto A, et al.
Br J Clin Pharmacol
. 2013 Aug;
77(6):929-38.
PMID: 23981115
Aim: The aim of this study is to investigate the incidence and risk of hepatic toxicity in patients receiving tyrosine kinase inhibitors (TKIs) through a large up-to-date meta-analysis of available...
12.
Risi E, Iacovelli R, Altavilla A, Alesini D, Palazzo A, Mosillo C, et al.
Urology
. 2013 Jun;
82(2):382-6.
PMID: 23800653
Objective: To collect and analyze clinical and pathological features of primitive neuroectodermal tumor (PNET)/Ewing sarcoma (EWS), a rare tumor occurring most commonly in bone and soft tissues of young people,...
13.
Iacovelli R, Palazzo A, Trenta P, Mezi S, Pellegrino D, Naso G, et al.
Am J Clin Oncol
. 2013 Feb;
37(6):611-5.
PMID: 23388560
Prognosis of metastatic renal cell carcinoma (mRCC) has markedly improved in the recent years. Several factors such as precocious diagnosis, better supportive care, and an increased number of targeted therapies...
14.
Passaro A, Trenta P, Conte D, Campenni G, De Benedetto A, Cortesi E
Thorac Surg Clin
. 2012 Apr;
22(2):243-9.
PMID: 22520292
Non-small-cell lung cancer remains the leading cause of cancer-related mortality in the United States and Europe. Most patients are diagnosed with metastatic disease for which chemotherapy remains the cornerstone of...
15.
Iacovelli R, Trenta P, Tuzi A, Palazzo A, Cortesi E
Am Surg
. 2011 Dec;
77(11):E248-9.
PMID: 22196640
No abstract available.
16.
Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G, et al.
J Natl Cancer Inst
. 2010 Dec;
103(1):21-30.
PMID: 21123833
Background: In a randomized trial with a median follow-up of 18.4 months, 6 months of induction chemotherapy with a three-drug regimen comprising 5-fluorouracil (by continuous infusion)-leucovorin, irinotecan, and oxaliplatin (FOLFOXIRI)...